Over the past decade, discoveries of mutations in epidermal growth factor receptor (EGFR) and rearrangements in echinoderm microtubule-associated protein-like 4 (EML4) anaplastic lymphoma kinase (ALK) genes have had a significant impact on NSCLC treatment. Here, ALK is linked to non-small cell lung carcinoma.